Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079470 | 0.90 | SMN1; SMN2 (0.40) | SMN1; SMN2GAAMEN1KMT2APKM | |
| SCHEMBL21296485 | 0.89 | GAA (0.40) | SMN1; SMN2GAAMEN1KMT2APKM | |
| SCHEMBL21296472 | 0.86 | ALDH1A1 (0.45) | SMN1; SMN2MEN1KMT2APKMLMNA | |
| SCHEMBL11890433 | 0.82 | ALDH1A1 (0.36) | SMN1; SMN2GAAMEN1KMT2APKM | |
| SCHEMBL4013481 | 0.81 | SMN1; SMN2 (0.33) | SMN1; SMN2GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL942541 | 0.81 | SMN1; SMN2 (0.32) | SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL941630 | 0.81 | PKM (0.33) | SMN1; SMN2GAAMEN1KMT2APKM | |
| SCHEMBL30824045 | 0.80 | L3MBTL1 (0.33) | SMN1; SMN2GAAPKMPOLBL3MBTL1 | |
| SCHEMBL4761780 | 0.80 | SMN1; SMN2 (0.32) | SMN1; SMN2GAAMEN1KMT2ALMNA | |
| SCHEMBL30950092 | 0.80 | F2RL1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101242832-B | Fused pyrazole as p38 MAP kinase inhibitors | HOFFMANN LA ROCHE | 2011-08-10 | — | — | CN | disclosed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| CN-101242832-A | Fused pyrazole as p38 MAP kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | CN | disclosed |
| EP-1919470-A1 | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
| CN-1926139-A | Fused pyrazole derivatives | HOFFMANN LA ROCHE (CH) | 2007-03-07 | — | — | CN | disclosed |
| WO-2007023105-A1 | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| EP-1737865-A1 | FUSED DERIVATIVES OF PYRAZOLE | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005085249-A1 | FUSED DERIVATIVES OF PYRAZOLE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | MAP3K1, MAPK1, MAP3K8 | SMN1; SMN2 2168/4885GAA 3888/4885MEN1 3629/4885 |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPKAPK2, MAPK1, MAP3K2 | SMN1; SMN2 852/4885GAA 2670/4885MEN1 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.